The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q-Reference-Cited by-同舟云学术

The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q

Published:2018-12-14 Issue:3 Volume:3 Page:351-358
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Lee Dawn,Brereton Nic,Dhanasiri Sujith,Kulasekararaj Austin

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s41669-018-0110-3.pdf

Reference21 articles.

1. Celgene Ltd. Revlimid®. Summary of product characteristics. 2014. http://www.medicines.org.uk/emc/medicine/19841/SPC/Revlimid . Accessed 13 Jan 2015.

2. Besa EC. Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues. Med Clin North Am. 1992;76(3):599–617.

3. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004:297–317.

4. Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006;106(10):2087–94.

5. Mallo M, Cervera J, Schanz J, Such E, Garcia-Manero G, Luño E, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011;25(1):110–20.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review;Journal of Oncology Pharmacy Practice;2020-07-12

2. Real-world evidence use in assessments of cancer drugs by NICE;International Journal of Technology Assessment in Health Care;2020-07-10

3. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective;Journal for ImmunoTherapy of Cancer;2020-07

4. Addressing uncertainty in cost-effectiveness case for lenalidomide;PharmacoEconomics & Outcomes News;2019-01